Patents by Inventor L. Smith

L. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070098719
    Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.
    Type: Application
    Filed: March 27, 2006
    Publication date: May 3, 2007
    Applicant: TolerRx, Inc.
    Inventors: L. Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig
  • Publication number: 20070041982
    Abstract: The present invention provides binding molecules that specifically bind to ILT3, e.g., human ILT3 (hILT3), on antigen presenting cells, such as for example, monocytes, macrophages and dendritic cells (DC), e.g., monocyte-derived dendritic cells (MDDC). The binding molecules of the invention are characterized by binding to hILT3 with high affinity and downmodulating immune responses in vitro, e.g., downmodulating alloimmune responses; the production of inflammatory cytokines by dendritic cells, e.g., monocyte-derived dendritic cells (MDDC); the upregulation of costimulatory molecules by DC, e.g., MDDC; and/or calcium flux in monocytes. In addition, the binding molecules upregulate the expression of inhibitory receptors on dendritic cells, e.g., immature dendritic cells. Surprisingly, these same binding molecules which downmodulate immune responses in vitro, are immunostimulatory in vivo. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof.
    Type: Application
    Filed: June 19, 2006
    Publication date: February 22, 2007
    Applicant: TolerRx, Inc.
    Inventors: Paul Ponath, Patricia Rao, Michael Rosenzweig, L. Smith, Jose Ponte
  • Publication number: 20060062953
    Abstract: A protective device for attaching to and protecting at least one article includes a cover having an attachment surface and a display surface opposing the attachment surface. An adhesive coating is applied to the attachment surface of the cover to facilitate adhesion of the cover to an article. A removable backing is releasably attached to the adhesive coating and at least one relief notch is formed in the cover through the attachment surface of the cover and terminates beneath the display surface of the cover.
    Type: Application
    Filed: September 17, 2004
    Publication date: March 23, 2006
    Inventors: Larry Trigg, Sam Lucente, Allison Johnson, Mohammad Samii, Paul Bradley, Arvind Gupta, Kara Johnson, Matthias Wieser, Matthew Adams, James Genis, L. Smith